Gynecologic Oncology Articles | Page 2

How Reliable Is PD-L1 Expression as a Predictor of Immune Response?
There is a great need—and opportunity—to improve ovarian cancer outcomes by understanding the immune milieu of ovarian cancers and harnessing the power of immunotherapy.
Endometrial Cancer Enters Immunotherapy Age
The tumor-site agnostic FDA approval of the PD-1 inhibitor pembrolizumab (Keytruda) for patients with microsatellite instability-high or mismatch repair deficient  solid tumors has helped propel endometrial cancer into the immunotherapy age.
Cisplatin Chemoradiation Proves Benefit in Stage IIIB Cervical Cancer
Umesh Mahantshetty, MD, shares his insight on the state of cervical cancer treatment in developing countries.
Tisotumab Vedotin Shows Clinical Benefit and Ongoing Responses in Cervical Cancer
A first-in-human study showed that the antibody drug conjugate tisotumab vedotin was well-tolerated and provided promising anti-tumor activity in patients with relapsed, recurrent, and/or metastatic cervical cancer. 
Pembrolizumab Demonstrates Safety and Efficacy in Cervical Cancer
In phase Ib results from the KEYNOTE-028 trial, pembrolizumab (Keytruda) was found to be active in cervical cancer while demonstrating safety results similar to previous studies with the PD-1 inhibitor.
FDA Accepts sBLA for Bevacizumab in First-Line Ovarian Cancer
The FDA has accepted a supplemental biologics license application for bevacizumab (Avastin) for the first-line treatment of advanced ovarian cancer.
Expert Discusses Immunotherapy Across Gynecologic Malignancies
Dmitriy Zamarin, MD, PhD, discusses the role of immunotherapy for patients with gynecologic malignancies.
Neoadjuvant Chemo Linked to Above 95% OS in Squamous Cell Cervical Cancer
Investigators sought to assess the efficacy of adjuvant surgery after concurrent chemoradiotherapy in patients with bulky squamous cell carcinoma of the uterine cervix
Hydrocortisone Reduces Hypersensitivity Reactions in Women With Gynecologic Cancers
Adding IV hydrocortisone to standard dexamethasone prophylaxis reduced the incidence of hypersensitivity reactions in women undergoing paclitaxel-based treatment for gynecologic cancers
Adjuvant CRT Linked to 83% Reduced Risk of Death in Endometrial Cancer
Women with node-positive stage IIIC endometrial cancer assigned to adjuvant chemoradiation therapy had better survival than those assigned to chemotherapy or radiation therapy alone.
Publication Bottom Border
Border Publication